BioSpace News Archive

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.

POINT Biopharma Global Inc. today announced details of the initial clinical trial in the Company’s pan-cancer Fibroblast Activation Protein-α (FAP-α) targeted program PNT2004, FRONTIER.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET.

Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel.

Endevica Bio , a company developing first-in-class peptide drug candidates with better safety and efficacy properties, appointed Daniel Marks, M.D. Ph.D. as Chief Medical Officer (CMO).

CoNextions® Inc. (www.conextionsmed.com), an innovator in tendon repair, announced that on May 11, 2022, only nineteen days after FDA 510(k) clearance to market the device, the first patient was treated with the CoNextions TR™ Tendon Repair System in a zone 2 flexor tendon in the little finger.

Shanghai Junshi Biosciences Co., Ltd announced that the China National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2022.

Celularity Inc. announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.